Masters Cap Cuts CV Therapeutics Stake To 1.3%
DOW JONES NEWSWIRES
WASHINGTON -- Masters Capital Management LLC reported cutting its stake in CV Therapeutics Inc. (CVTX) below 5%, to 1.29%, in an amended Schedule 13G filed Monday with the Securities and Exchange Commission.
According to the filing, as of Dec. 31, 2003, Masters Capital beneficially owned 310,000 shares derived from options on the common stock of the Palo Alto, Calif.-based biopharmaceutical company.
In a previous 13G filing, Masters Capital reported holding 1,494,800 CV Therapeutics common shares, or a 5.14% stake, at Dec. 8, 2003.
A Schedule 13G denotes a passive investment stake in a company. Filers aren't required to provide a reason for any changes in stake, and aren't required to detail any transactions. |
